Naltrexone (Naltraccord) tab 50 mg: Supply issue

Supply issue Active

Teva, the supplier of naltrexone hydrochloride tab 50 mg advises that stock of Naltraccord (Pharmacode 2380374) is low.

6 November 2024 | Update

Resupply of the Medsafe-approved product has been delayed. There is still ample supply of the listed alternative, Naltrexone Max Health (Pharmacode: 2692961).

Affected product

  • Chemical: Naltrexone hydrochloride
  • Presentation: Tab 50 mg
  • Brand: Naltraccord
  • Pharmacode: 2380374
  • Subsidy: $83.33
  • Measure / Qty: per 30

Schedule listing for naltrexone(external link)

Alternative product

Teva has found an alternative, Naltrexone Max Health. It can be ordered from Onelink. It is not Medsafe registered, so will have to be prescribed and dispensed in line with section 29 of the Medicines Act.

  • Chemical: naltrexone hydrochloride
  • Brand: Naltrexone Max Health
  • Presentation: 50 mg tablet
  • Pharmacode: 2692961
  • Price: $102.60
  • Pack size: 30
  • Section 29 wastage and claimable rules apply

We listed the Revia brand (2689049) as an alternative last month. Unfortunately, stock could not arrive in time to support this supply issue. 

Prescribing and supplying an unapproved medicine

Section 29 of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – such as, a doctor. 

We know supplying a medicine under section 29 is not ideal. In this case, however, this will allow patients to be able to access an appropriate treatment. 

We apologise for any inconvenience this causes. 

Advice for prescribing under section 29 – BPAC website(external link) 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website (external link)

Medsafe’s section 29 Declaration / Notification Form [DOC](external link)

What patients need to know about unapproved medicines – Healthify website(external link)

Expected resupply

Teva advises the registered stock will not be available until at least February 2025.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.  

Sign up to our email list for regular emails about supply issues and more(external link)